secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001628280-23-024042
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

China NMPA approves Zai Lab's VYVGART for generalized myasthenia gravis
-----------------------------------------------------------------------

- NMPA approved VYVGART (efgartigimod alfa) as add-on for anti-AChR+ gMG adults.
- Phase 3 ADAPT: 68% responders on MG-ADL vs 30% placebo (p<0.0001) in first cycle.
- Zai Lab to seek National Reimbursement Drug List inclusion for broader patient access.
- Zai Lab holds exclusive license from argenx to develop/commercialize in mainland China, HK, Macau, Taiwan.
- VYVGART is the first approved FcRn antagonist for gMG in China; ~200,000 MG patients in country.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023024042/0001628280-23-024042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828023024042/zlab-20230630.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-024042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer